Zantrene® (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a high dose, less cardiotoxic chemotherapeutic. The recent identification that Zantrane® is an highly potent FTO inhibitor has driven intense scientific and clinical interest in Zantrene as a rapidly translatable pharmaceutical able to target the m6A RNA methylation pathway. History of Zantrene® Zantrene was originally developed by Lederle Laboratories in the 1970s as a lower cardiotoxic alternative to the anthracycline chemotherapeutics. Lederle trialled Zantrene on…

Latest News